Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Insights

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy area is Cytotoxic T lymphocyte associated antigen-4 (CTLA-4). It is found on the surface of T –cells and is continuously involved in the inhibitory T-cell responses.CTLA-4  (Cytotoxic T-lymphocyte-associated protein 4), also known as CD152  is a protein receptor that down regulates the immune system by consistently affecting the T cell responses. It is generally encoded by CTLA-4 gene in humans.

The current Oncology market is steered by Bristol Myers Squibb with Yervoy (monoclonal antibody) approved for melanoma. The annual sales for Yervoy have increased by 23% in US and 56% in Non-US cities in 2014 as compared to 2013.

Several other companies are actively working which includes Astrazeneca, Merck, Roche & Pfizer. There are several drugs under pipeline among which Tremelimumab had shown inordinate results in clinical studies for treating malignant mesothelioma.

DelveInsight’s, Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) – Competitive Landscape, Pipeline and Market Analysis, 2015 provides the in-depth analysis of the pipeline assets across Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) targets & inhibitors. The prime foucs of this report is to track competitor pipeline molecules, related research activities, t, collaborations, in-licensing and out-licensing deals. Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) – Competitive Landscape, Pipeline and Market Analysis, 2015 Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to optimize portfolios and to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1450 as a single user license, USD 2900 as a site license and USD 4000 as a Global/Enterprise License.

For more information on our Oncology Reports email us at info@delveInsight.com

About:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.